Tag: CTLA-4 inhibitor
Immunotherapy delays deterioration in health-related quality of life in metastatic NSCLC
Characteristics of long-term survivors in the CASPIAN trial
Second-line nivolumab/ipilimumab boost improves ORR in metastatic urothelial carcinoma
Biomarkers predict response to immune nivolumab (± ipilimumab) in advanced RCC
AK104 plus chemotherapy promising first-line option for gastric cancer
NIPICOL: New data on optimal ICI treatment duration in MSI/dMMR mCRC
HIMALAYA: Durvalumab ± tremelimumab new first-line option for unresectable HCC
Immune chemo-sensitisation looks promising in microsatellite-stable mCRC
Consistent benefit of anti-PD-1 therapy for oesophageal and gastric cancer
ctDNA highly predictive in HER2-positive, advanced gastric or gastro-oesophageal junction cancer
Nivolumab/ipilimumab continues to provide survival benefit in unresectable MPM
Three-year OS follow-up from CASPIAN trial
IFN-γ signature predicts response to immunotherapy
Updated results of SECOMBIT trial
Durable intracranial responses with nivolumab/ipilimumab
Modified ipilimumab schedule reduces risk of grade 3/4 adverse events
Optimal neoadjuvant dose ipilimumab/nivolumab in stage III urothelial cancer
Sustained efficacy of nivolumab/ipilimumab plus 2 cycles of chemotherapy in NSCLC
Benefit of both I-O/chemo combo and I-O/I-O combo over chemotherapy alone in oesophageal squamous cell cancer
